Healthcare News: April HCPCS update brings new codes, guidance for biosimilar biological products

Why This Topic Matters

The update reflects changes that affect how certain biologic products are reported and processed for Medicare claims. It also highlights a policy change that reduces reliance on manufacturer-specific biosimilar modifiers beginning on the stated effective date.

Article Sections

1. CMS Transmittal 3997 overview

   Introduces the HCPCS drug and biological code update and the general categories of changes addressed in the transmittal. It also notes the type of administrative information provided to Medicare contractors.

2. Updated HCPCS code details

   Summarizes the newly revised HCPCS items discussed in the update, including biosimilar product reporting and one cellular immunotherapy-related code. It also notes the effective date and contractor-related administrative information.

3. Medicare biosimilar payment policy and modifier changes

   Describes the Medicare Part B policy context behind the biosimilar reporting update and the resulting change to modifier requirements. It explains the policy shift at a general level for claims processing.

4. Summary of April 1 claim impacts

   Provides a brief recap of the effective-date impact on HCPCS code reporting and associated Medicare claim processing. It reiterates the overall scope of the update without detailing coding instructions.